Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

T Cell Subset and Stimulation Strength-Dependent Modulation of T Cell Activation by Kv1.3 Blockers.

Fung-Leung WP, Edwards W, Liu Y, Ngo K, Angsana J, Castro G, Wu N, Liu X, Swanson RV, Wickenden AD.

PLoS One. 2017 Jan 20;12(1):e0170102. doi: 10.1371/journal.pone.0170102. eCollection 2017.

2.

Computational Studies of Venom Peptides Targeting Potassium Channels.

Chen R, Chung SH.

Toxins (Basel). 2015 Dec 1;7(12):5194-211. doi: 10.3390/toxins7124877. Review.

3.

Designer and natural peptide toxin blockers of the KcsA potassium channel identified by phage display.

Zhao R, Dai H, Mendelman N, Cuello LG, Chill JH, Goldstein SA.

Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):E7013-21. doi: 10.1073/pnas.1514728112. Epub 2015 Dec 1.

4.

Computational Insights of the Interaction among Sea Anemones Neurotoxins and Kv1.3 Channel.

Sabogal-Arango A, Barreto GE, Ramírez-Sánchez D, González-Mendoza J, Barreto V, Morales L, González J.

Bioinform Biol Insights. 2014 Apr 15;8:73-81. doi: 10.4137/BBI.S13403. eCollection 2014.

5.

Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma.

Koshy S, Huq R, Tanner MR, Atik MA, Porter PC, Khan FS, Pennington MW, Hanania NA, Corry DB, Beeton C.

J Biol Chem. 2014 May 2;289(18):12623-32. doi: 10.1074/jbc.M113.517037. Epub 2014 Mar 18.

6.

hERG potassium channel blockage by scorpion toxin BmKKx2 enhances erythroid differentiation of human leukemia cells K562.

Ma J, Hu Y, Guo M, Huang Z, Li W, Wu Y.

PLoS One. 2013 Dec 26;8(12):e84903. doi: 10.1371/journal.pone.0084903. eCollection 2013.

7.

Immunosuppressive peptides and their therapeutic applications.

Thell K, Hellinger R, Schabbauer G, Gruber CW.

Drug Discov Today. 2014 May;19(5):645-53. doi: 10.1016/j.drudis.2013.12.002. Epub 2013 Dec 11. Review.

8.

Intracellular trafficking of the KV1.3 potassium channel is regulated by the prodomain of a matrix metalloprotease.

Nguyen HM, Galea CA, Schmunk G, Smith BJ, Edwards RA, Norton RS, Chandy KG.

J Biol Chem. 2013 Mar 1;288(9):6451-64. doi: 10.1074/jbc.M112.421495. Epub 2013 Jan 8.

9.

A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3.

Pennington MW, Harunur Rashid M, Tajhya RB, Beeton C, Kuyucak S, Norton RS.

FEBS Lett. 2012 Nov 16;586(22):3996-4001. doi: 10.1016/j.febslet.2012.09.038. Epub 2012 Oct 9.

10.

Exploiting the nephrotoxic effects of venom from the sea anemone, Phyllodiscus semoni, to create a hemolytic uremic syndrome model in the rat.

Mizuno M, Ito Y, Morgan BP.

Mar Drugs. 2012 Jul;10(7):1582-604. doi: 10.3390/md10071582. Epub 2012 Jul 23. Review.

11.

OLIG2 over-expression impairs proliferation of human Down syndrome neural progenitors.

Lu J, Lian G, Zhou H, Esposito G, Steardo L, Delli-Bovi LC, Hecht JL, Lu QR, Sheen V.

Hum Mol Genet. 2012 May 15;21(10):2330-40. doi: 10.1093/hmg/dds052. Epub 2012 Feb 17.

12.

KCa1.1 potassium channels regulate key proinflammatory and invasive properties of fibroblast-like synoviocytes in rheumatoid arthritis.

Hu X, Laragione T, Sun L, Koshy S, Jones KR, Ismailov II, Yotnda P, Horrigan FT, Gulko PS, Beeton C.

J Biol Chem. 2012 Feb 3;287(6):4014-22. doi: 10.1074/jbc.M111.312264. Epub 2011 Nov 10.

13.

Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases.

Chi V, Pennington MW, Norton RS, Tarcha EJ, Londono LM, Sims-Fahey B, Upadhyay SK, Lakey JT, Iadonato S, Wulff H, Beeton C, Chandy KG.

Toxicon. 2012 Mar 15;59(4):529-46. doi: 10.1016/j.toxicon.2011.07.016. Epub 2011 Aug 12. Review.

14.

Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases.

Beeton C, Pennington MW, Norton RS.

Inflamm Allergy Drug Targets. 2011 Oct;10(5):313-21. Review.

15.

D-Maurocalcine, a pharmacologically inert efficient cell-penetrating peptide analogue.

Poillot C, Dridi K, Bichraoui H, Pêcher J, Alphonse S, Douzi B, Ronjat M, Darbon H, De Waard M.

J Biol Chem. 2010 Oct 29;285(44):34168-80. doi: 10.1074/jbc.M110.104919. Epub 2010 Jul 7.

16.

Potassium channel modulation by a toxin domain in matrix metalloprotease 23.

Rangaraju S, Khoo KK, Feng ZP, Crossley G, Nugent D, Khaytin I, Chi V, Pham C, Calabresi P, Pennington MW, Norton RS, Chandy KG.

J Biol Chem. 2010 Mar 19;285(12):9124-36. doi: 10.1074/jbc.M109.071266. Epub 2009 Dec 4.

17.

The functional network of ion channels in T lymphocytes.

Cahalan MD, Chandy KG.

Immunol Rev. 2009 Sep;231(1):59-87. doi: 10.1111/j.1600-065X.2009.00816.x. Review.

18.

Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes.

Pennington MW, Beeton C, Galea CA, Smith BJ, Chi V, Monaghan KP, Garcia A, Rangaraju S, Giuffrida A, Plank D, Crossley G, Nugent D, Khaytin I, Lefievre Y, Peshenko I, Dixon C, Chauhan S, Orzel A, Inoue T, Hu X, Moore RV, Norton RS, Chandy KG.

Mol Pharmacol. 2009 Apr;75(4):762-73. doi: 10.1124/mol.108.052704. Epub 2009 Jan 2.

19.

Integrating the discovery pipeline for novel compounds targeting ion channels.

Bulaj G.

Curr Opin Chem Biol. 2008 Aug;12(4):441-7. doi: 10.1016/j.cbpa.2008.07.012. Epub 2008 Aug 3. Review.

20.

K+ channel modulators for the treatment of neurological disorders and autoimmune diseases.

Wulff H, Zhorov BS.

Chem Rev. 2008 May;108(5):1744-73. doi: 10.1021/cr078234p. Review. No abstract available.

Supplemental Content

Support Center